Mynd (MYND) news
Recent news
Biocon's Shaw: Biosimilars a very attractive segment
Biocon, India’s largest biopharmaceutical company, has positioned itself as a key player in the global biosimilars market, with its chairman and managing director, Kiran Mazumdar-Shaw, emphasizing the segment’s growing potential. The company recently received approval for its Glargine biosimilar in…
AInvest Wire · 1d agoDow Jones unofficially closes up 189.88 points, or 0.37%, at 51,844.83
The Dow Jones Industrial Average (DJIA) rose 189.88 points, or 0.37%, to close at 51,844.83 on Friday, reflecting modest gains amid ongoing market adjustments. The index, which tracks the performance of 30 large, publicly traded U.S. companies, has undergone recent changes to its composition, with…
AInvest Wire · 1d agoMynd.ai announces CEO and CFO transition
AInvest Wire · 6d agoMynd.ai reports first half 2026 results as turnaround gains momentum; adjusted EEBDA improves 52%, operating expenses reduced 35%
AInvest Wire · Aug 27, 2026Mynd.ai, Inc. receives NYSE American approval of compliance plan and extension through December 2027
Mynd.ai, Inc. (NYSE American: MYND) has received approval from NYSE American for its compliance plan, granting the company until December 2, 2027, to regain compliance with the exchange’s continued listing standards. The approval follows the submission of a plan by the company on July 2, 2026,…
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.